AstraZeneca Lung Drug Shows Success in Late-Stage Trials, Boosting Shares

AstraZeneca's drug for chronic lung disease has met its primary goals in late-stage trials, demonstrating its ability to reduce flare-ups and leading to a rise in the company's shares, as reported by the Wall Street Journal.